Marie E. Faughnan

MD, MSc

Scientist

Biography

Dr. Marie E. Faughnan is a Respirologist and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital. She is an Associate Professor at the University of Toronto. Dr. Faughnan is a clinical epidemiologist, with a research focus on clinical and mechanistic aspects of vascular malformations, with a specific expertise in hereditary hemorrhagic telangiectasia (HHT). Dr. Faughnan is the Director of the Toronto Hereditary Hemorrhagic Telangiectasia Centre and the Scientific Director for CureHHT. Dr. Faughnan has also led the development and publication of the first International HHT Guidelines.

Recent Publications

  1. Parikh, H, Lui, E, Faughnan, ME, Al-Hesayen, A, Segovia, S, Gupta, S et al.. Supine vs upright exercise in patients with hepatopulmonary syndrome and orthodeoxia: study protocol for a randomized controlled crossover trial. Trials. 2021;22 (1):683. doi: 10.1186/s13063-021-05633-7. PubMed PMID:34625098 PubMed Central PMC8500814.
  2. Thompson, KP, Nelson, J, Kim, H, Weinsheimer, SM, Marchuk, DA, Lawton, MT et al.. Utility of modified Rankin Scale for brain vascular malformations in hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2021;16 (1):390. doi: 10.1186/s13023-021-02012-y. PubMed PMID:34538258 PubMed Central PMC8451134.
  3. Wetzel-Strong, SE, Weinsheimer, S, Nelson, J, Pawlikowska, L, Clark, D, Starr, MD et al.. Pilot investigation of circulating angiogenic and inflammatory biomarkers associated with vascular malformations. Orphanet J Rare Dis. 2021;16 (1):372. doi: 10.1186/s13023-021-02009-7. PubMed PMID:34479577 PubMed Central PMC8414780.
  4. Faughnan, ME, Mager, JJ, Hetts, SW, Palda, VA, Ratjen, F. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Ann Intern Med. 2021;174 (7):1035-1036. doi: 10.7326/L21-0067. PubMed PMID:34280351 .
  5. Wu, V, Lee, JM, Vozoris, NT, Faughnan, ME. Weekly epistaxis duration as an indicator of epistaxis severity in hereditary hemorrhagic telangiectasia-Preliminary results from a randomized controlled trial. Laryngoscope Investig Otolaryngol. 2021;6 (3):370-375. doi: 10.1002/lio2.561. PubMed PMID:34195356 PubMed Central PMC8223446.
  6. Keränen, S, Suutarinen, S, Mallick, R, Laakkonen, JP, Guo, D, Pawlikowska, L et al.. Cyclo-oxygenase 2, a putative mediator of vessel remodeling, is expressed in the brain AVM vessels and associates with inflammation. Acta Neurochir (Wien). 2021;163 (9):2503-2514. doi: 10.1007/s00701-021-04895-z. PubMed PMID:34185176 PubMed Central PMC8357659.
  7. Zhang, Q, Wang, C, Cannavicci, A, Faughnan, ME, Kutryk, MJB. Endoglin deficiency impairs VEGFR2 but not FGFR1 or TIE2 activation and alters VEGF-mediated cellular responses in human primary endothelial cells. Transl Res. 2021;235 :129-143. doi: 10.1016/j.trsl.2021.04.005. PubMed PMID:33894400 PubMed Central PMC8328903.
  8. Thompson, KP, Nelson, J, Kim, H, Pawlikowska, L, Marchuk, DA, Lawton, MT et al.. Predictors of mortality in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2021;16 (1):12. doi: 10.1186/s13023-020-01579-2. PubMed PMID:33407668 PubMed Central PMC7789194.
  9. Kilian, A, Clancy, MS, Olitsky, S, Gossage, JR, Faughnan, ME. Screening for pulmonary and brain vascular malformations is the North American standard of care for patients with hereditary hemorrhagic telangiectasia (HHT): A survey of HHT Centers of Excellence. Vasc Med. 2021;26 (1):53-55. doi: 10.1177/1358863X20974452. PubMed PMID:33375920 PubMed Central PMC7879226.
  10. Han, Z, Shaligram, S, Faughnan, ME, Clark, D, Sun, Z, Su, H et al.. Reduction of endoglin receptor impairs mononuclear cell-migration. Explor Med. 2020;1 :136-148. doi: 10.37349/emed.2020.00010. PubMed PMID:32954380 PubMed Central PMC7500529.
Search PubMed

Affiliations & Other Activities

  • Director, Pulmonary Function Laboratory, St. Michael’s Hospital
  • Director, Toronto Hereditary Hemorrhagic Telangiectasia, The Hospital for Sick Children
X